UGCG and Gaucher disease: Glucosylceramide synthase inhibitors such as eliglustat support the efficacy and safety of substrate reduction with extra-focused inhibitors; however, some patients also reported diarrhea, abdominal pain, and abnormal nerve conduction test results in Gaucher disease [33-35].